Firms Face Uphill Battle To Break Open Chronic Total Occlusion Market
This article was originally published in The Gray Sheet
Executive Summary
Despite recent advances in specialized guidewires, industry has struggled to develop effective new technologies to aid in opening coronary chronic total occlusions, according to interventionalists
You may also be interested in...
New Occlusion Devices May Fill Innovation Gap – CTO Summit Panel
Progress in the development of new technologies for treating chronic total occlusions is finally accelerating after years of stagnation, experts reported at the CTO Summit Feb. 5-6 in New York
New Occlusion Devices May Fill Innovation Gap – CTO Summit Panel
Progress in the development of new technologies for treating chronic total occlusions is finally accelerating after years of stagnation, experts reported at the CTO Summit Feb. 5-6 in New York
Crosser cleared for CTOs
FlowCardia will launch its Crosser 14 high frequency ultrasound crossing catheter in the United States within the quarter, according to Director of Marketing Mark Page. The firm announced 510(k) clearance for the device, which uses a vibrating tip to facilitate guidewire passage through coronary chronic total occlusions, on Jan. 23. FlowCardia also announced Jan. 25 that three Crosser devices for peripheral CTOs were approved in Europe. Firms have struggled to enter the coronary CTO market with specialty devices (1"The Gray Sheet" March 6, 2006, p. 13)...